Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,486.40
(
0.32%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.41
(
0.00%
)
Bitcoin
73,068.63
(
0.12%
)
News Focus
News Focus
Post# of 257382
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122860
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 140702

Thursday, 05/09/2013 4:40:51 PM

Thursday, May 09, 2013 4:40:51 PM

Post# of 257382
ONTY—Bad clinical news on PX-866 buried in the 1Q13 PR:

http://finance.yahoo.com/news/oncothyreon-reports-first-quarter-2013-200500701.html

The Phase 2 portion of this trial in NSCLC enrolled 95 patients, 48 in the PX-866 plus docetaxel group and 47 in the docetaxel alone group. This portion of the trial is now concluded and did not demonstrate an improvement in progression-free survival in the combination group when compared to docetaxel alone, the primary endpoint of the trial.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today